

Fenghai Duan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4829646/publications.pdf>

Version: 2024-02-01

66
papers

13,434
citations

126907

33
h-index

118850

62
g-index

67
all docs

67
docs citations

67
times ranked

13717
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung Cancer. <i>Radiology</i> , 2022, 302, 684-692.	7.3	9
2	Social Genomics as a Framework for Understanding Health Disparities Among Adolescent and Young Adult Cancer Survivors: A Commentary. <i>JCO Precision Oncology</i> , 2022, , .	3.0	3
3	FDG-PET/CT and Pathology in Newly Diagnosed Head and Neck Cancer: ACRIN 6685 Trial, FDG-PET/CT cNO. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 1230-1239.	1.9	6
4	Distinguishing Smoking-Related Lung Disease Phenotypes Via Imaging and Molecular Features. <i>Chest</i> , 2021, 159, 549-563.	0.8	6
5	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. <i>Tomography</i> , 2021, 7, 139-152.	1.8	4
6	Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1118-1126.	1.1	6
7	A simple assessment of lung nodule location for reduction in unnecessary invasive procedures. <i>Journal of Thoracic Disease</i> , 2021, 13, 4207-4216.	1.4	0
8	Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers. <i>Thorax</i> , 2021, 76, 272-280.	5.6	12
9	Validation of the BRODERS classifier (Benign versus aggressive nodule Evaluation using) Tj ETQq1 1 0.784314 rgBT /Overlock European Respiratory Journal, 2021, 57, 2002485.	6.7	16
10	Implementation of FDG-PET/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 415-427.	1.0	0
11	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , 2020, 10, 354-362.	2.1	9
12	Multicenter Trial of [¹⁸ F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the NO Neck: Results From ACRIN 6685. <i>Journal of Clinical Oncology</i> , 2019, 37, 1704-1712.	1.6	80
13	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113
14	Hospice Admission and Survival After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 427-433.	5.0	13
15	Intended Versus Inferred Treatment After ¹⁸ F-Fluoride PET Performed for Evaluation of Osseous Metastatic Disease in the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2018, 59, 421-426.	5.0	12
16	Novel high-resolution computed tomography-based radiomic classifier for screen-identified pulmonary nodules in the National Lung Screening Trial. <i>PLoS ONE</i> , 2018, 13, e0196910.	2.5	32
17	Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial—American College of Radiology Imaging Network Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 392-402.	3.2	47
18	Interval lung cancer after a negative CT screening examination: CT findings and outcomes in National Lung Screening Trial participants. <i>European Radiology</i> , 2017, 27, 3249-3256.	4.5	18

#	ARTICLE	IF	CITATIONS
19	Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1969-1983.	6.4	62
20	Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 17-24.	6.4	98
21	Applying Multivariate Adaptive Splines to Identify Genes With Expressions Varying After Diagnosis in Microarray Experiments. <i>Cancer Informatics</i> , 2017, 16, 117693511770538.	1.9	3
22	Normative reference values of thoracic aortic diameter in American College of Radiology Imaging Network (ACRIN 6654) arm of National Lung Screening Trial. <i>Clinical Imaging</i> , 2016, 40, 936-943.	1.5	31
23	Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry. <i>Oncologist</i> , 2016, 21, 1079-1084.	3.7	11
24	Pretreatment ¹⁸ F-FDG PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235. <i>Journal of Nuclear Medicine</i> , 2016, 57, 842-848.	5.0	75
25	Association of Coronary Artery Calcification and Mortality in the National Lung Screening Trial: A Comparison of Three Scoring Methods. <i>Radiology</i> , 2015, 276, 82-90.	7.3	239
26	Lung Cancer Susceptibility, Ethnicity, and the Benefits of Computed Tomography Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1394-1396.	5.6	1
27	¹⁸ F-Fluoride PET Used for Treatment Monitoring of Systemic Cancer Therapy: Results from the National Oncologic PET Registry. <i>Journal of Nuclear Medicine</i> , 2015, 56, 222-228.	5.0	86
28	Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1060-1067.	5.6	115
29	Noninvasive Computed Tomography-based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 737-744.	5.6	50
30	Pretreatment FDG-PET Metrics in Stage III Non-Small Cell Lung Cancer: ACRIN 6668/RTOG 0235. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv004-djv004.	6.3	59
31	Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by ¹⁸ F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687. <i>Journal of Nuclear Medicine</i> , 2015, 56, 354-360.	5.0	55
32	Regional Lymph Node Uptake of [18F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 597-605.	0.8	19
33	A Phase II Study of ¹⁸ F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1681-1689.	5.0	73
34	Impact of lung cancer screening results on participant health-related quality of life and state anxiety in the National Lung Screening Trial. <i>Cancer</i> , 2014, 120, 3401-3409.	4.1	129
35	Projected Outcomes Using Different Nodule Sizes to Define a Positive CT Lung Cancer Screening Examination. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	93
36	An AUC-Like Index for Agreement Assessment. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 893-907.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Reply to J.-S. Ryu et al and A.T. Berman et al. Journal of Clinical Oncology, 2014, 32, 1632-1633.	1.6	0
38	Impact of ¹⁸ F-Fluoride PET on Intended Management of Patients with Cancers Other Than Prostate Cancer: Results from the National Oncologic PET Registry. Journal of Nuclear Medicine, 2014, 55, 1054-1061.	5.0	40
39	Impact of ¹⁸ F-Fluoride PET in Patients with Known Prostate Cancer: Initial Results from the National Oncologic PET Registry. Journal of Nuclear Medicine, 2014, 55, 574-581.	5.0	81
40	Results of the Two Incidence Screenings in the National Lung Screening Trial. New England Journal of Medicine, 2013, 369, 920-931.	27.0	465
41	Prediction of Survival by [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non-Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial. Journal of Clinical Oncology, 2013, 31, 3823-3830.	1.6	162
42	Results of Initial Low-Dose Computed Tomographic Screening for Lung Cancer. New England Journal of Medicine, 2013, 368, 1980-1991.	27.0	884
43	Examining whether lung screening changes risk perceptions: National Lung Screening Trial participants at 1-year follow-up. Cancer, 2013, 119, 1306-1313.	4.1	33
44	Impact of ¹⁸ F-FDG PET Used After Initial Treatment of Cancer: Comparison of the National Oncologic PET Registry 2006 and 2009 Cohorts. Journal of Nuclear Medicine, 2012, 53, 831-837.	5.0	34
45	Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: A report from the Children's Oncology Group. Genes Chromosomes and Cancer, 2012, 51, 662-674.	2.8	53
46	The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis. Hepatology, 2012, 55, 1529-1539.	7.3	59
47	Can Tumor FDG-PET Scan Uptake (SUV) Predict Local Control in Stage III NSCLC? Preliminary Results from ACRIN 6668/RTOG 0235. International Journal of Radiation Oncology Biology Physics, 2011, 81, S134-S135.	0.8	1
48	Impact of Dedicated Brain PET on Intended Patient Management in Participants of the National Oncologic PET Registry. Molecular Imaging and Biology, 2011, 13, 161-165.	2.6	26
49	Genomic and Clinical Analysis of Amplification of the 13q31 Chromosomal Region in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2011, 17, 1463-1473.	7.0	60
50	The National Lung Screening Trial: Overview and Study Design. Radiology, 2011, 258, 243-253.	7.3	992
51	Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. New England Journal of Medicine, 2011, 365, 395-409.	27.0	8,392
52	National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository Originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): Design, Intent, and Availability of Specimens for Validation of Lung Cancer Biomarkers. Journal of Thoracic Oncology, 2010, 5, 1502-1506.	1.1	30
53	Large scale analysis of positional effects of single-base mismatches on microarray gene expression data. BioData Mining, 2010, 3, 2.	4.0	18
54	PET and PET/CT Reports: Observations from the National Oncologic PET Registry. Journal of Nuclear Medicine, 2010, 51, 158-163.	5.0	31

#	ARTICLE	IF	CITATIONS
55	Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 661-672.	2.8	83
56	Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. <i>Proteome Science</i> , 2009, 7, 8.	1.7	46
57	OTK18 Levels in Plasma and Cerebrospinal Fluid Correlate with Viral Load and CD8 T-cells in Normal and AIDS Patients. <i>Journal of NeuroImmune Pharmacology</i> , 2008, 3, 230-235.	4.1	4
58	HIV-1 Activates Proinflammatory and Interferon-Inducible Genes in Human Brain Microvascular Endothelial Cells: Putative Mechanisms of Blood-Brain Barrier Dysfunction. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 697-711.	4.3	49
59	Erratum to "CSF proteomic fingerprints for HIV-associated cognitive impairment". <i>Journal of Neuroimmunology</i> , 2008, 205, 161.	2.3	0
60	Cultured Lung Fibroblasts from Ovalbumin-Challenged "Asthmatic" Mice Differ Functionally from Normal. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 37, 424-430.	2.9	45
61	Intercenter reliability and validity of the rhesus macaque GeneChip. <i>BMC Genomics</i> , 2007, 8, 61.	2.8	17
62	CSF proteomic fingerprints for HIV-associated cognitive impairment. <i>Journal of Neuroimmunology</i> , 2007, 192, 157-170.	2.3	57
63	Statistical Methodologies for Analyzing Genomic Data. , 2006, , 607-621.		0
64	Correcting the loss of cell-cycle synchrony in clustering analysis of microarray data using weights. <i>Bioinformatics</i> , 2004, 20, 1766-1771.	4.1	9
65	African-American/White differences in breast carcinoma. <i>Cancer</i> , 2004, 101, 1293-1301.	4.1	110
66	The Hinge of the Human Papillomavirus Type 11 E2 Protein Contains Major Determinants for Nuclear Localization and Nuclear Matrix Association. <i>Journal of Virology</i> , 2000, 74, 3761-3770.	3.4	61